In vivo cancer biomarkers of esophageal neoplasia.

The emergence of in vivo cancer biomarkers is promising tool for early detection, risk stratification, and therapeutic intervention in the esophagus, where adenocarcinoma is increasing at a rate that is faster than any other in industrialized nations. Exciting advances in target identification, probe development, and optical instrumentation are creating tremendous new opportunities for advancing techniques of molecular imaging. Progress in these areas is being made with small animal models of esophageal cancer using surgical approaches to induce reflux of acid and bile, and these findings are beginning to be evaluated in the clinic. Further identification of relevant targets, characterization of specific probes, and development of endoscopic imaging technologies are needed to further this direction in the field of molecular medicine. In the future, new methods that use in vivo cancer biomarkers for the early detection of neoplastic changes in the setting of Barrett's esophagus will become available.

[1]  M. Omary,et al.  Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. , 1996, The Journal of clinical investigation.

[2]  H. Sugihara,et al.  Thioproline inhibits development of esophageal adenocarcinoma induced by gastroduodenal reflux in rats. , 2003, Carcinogenesis.

[3]  G. Giannelli,et al.  Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. , 1997, Science.

[4]  G Van Belle,et al.  Observer variation in the diagnosis of dysplasia in Barrett's esophagus. , 1988, Human pathology.

[5]  K. Okita,et al.  Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer , 2003, British Journal of Cancer.

[6]  A. Ullrich,et al.  Molecular targets for breast cancer therapy and prevention , 2001, Nature Medicine.

[7]  V. Moreno,et al.  Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973–1995 , 2002, International journal of cancer.

[8]  L. Koppert,et al.  The molecular biology of esophageal adenocarcinoma , 2005, Journal of surgical oncology.

[9]  J. McKay,et al.  Matrix metalloproteinase‐1 is associated with poor prognosis in oesophageal cancer , 1998, The Journal of pathology.

[10]  M. Llinás,et al.  Peptide Ligands for the Fibronectin Type II Modules of Matrix Metalloproteinase 2 (MMP-2)* , 2003, The Journal of Biological Chemistry.

[11]  J. Goldblum,et al.  Original contributionThe diagnosis of low-grade dysplasia in Barrett’s esophagus and its implications for disease progression , 2000 .

[12]  H. Appelman,et al.  Dysplasia of the gut: the diagnosis is harder than it seems. , 2002, Journal of clinical gastroenterology.

[13]  M. Feith,et al.  COX2 expression, angiogenesis, proliferation and survival in Barrett's cancer. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[14]  H. Yamamoto,et al.  Matrix metalloproteinase matrilysin (MMP-7) participates in the progression of human gastric and esophageal cancers. , 1998, International journal of oncology.

[15]  H. Parkman,et al.  Heartburn--a serious symptom. , 1999, The New England journal of medicine.

[16]  J. Goldblum,et al.  Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. , 1999, Gastrointestinal endoscopy.

[17]  Christopher H Contag,et al.  Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. , 2008, Nature medicine.

[18]  W. Birchmeier,et al.  The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells , 1993, The Journal of cell biology.

[19]  Kenneth K Wang,et al.  Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus , 1998, The American Journal of Gastroenterology.

[20]  S. Piantadosi,et al.  Chemoprevention for Barrett's esophagus trial. Design and outcome measures. , 2003, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[21]  R. Odze,et al.  Neoplastic precursor lesions in Barrett's esophagus. , 2007, Gastroenterology clinics of North America.

[22]  S. Spechler,et al.  Barrett's esophagus: chemoprevention. , 2003, Gastrointestinal endoscopy clinics of North America.

[23]  Carissa A. Sanchez,et al.  Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. , 2000, Journal of the National Cancer Institute.

[24]  M. Stolte,et al.  Barrett’s esophagus: Histopathologic definitions and diagnostic criteria , 2004, World Journal of Surgery.

[25]  Toshikazu Nakamura,et al.  NK4 gene therapy targeting HGF-Met and angiogenesis. , 2008, Frontiers in bioscience : a journal and virtual library.

[26]  D. Bottaro,et al.  Targeting the c-Met Signaling Pathway in Cancer , 2006, Clinical Cancer Research.

[27]  D. Beer,et al.  Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  M. Omary,et al.  Altered sodium-hydrogen exchange activity is a mechanism for acid-induced hyperproliferation in Barrett's esophagus. , 1998, American journal of physiology. Gastrointestinal and liver physiology.

[29]  Kenneth K Wang,et al.  Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. , 2002, Gastroenterology.

[30]  R. Fitzgerald,et al.  Molecular basis of Barrett’s oesophagus and oesophageal adenocarcinoma , 2006, Gut.

[31]  J. Nesland,et al.  The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. , 2006, Gynecologic oncology.

[32]  K. Sugimachi,et al.  The clinical significance of MMP-1 expression in oesophageal carcinoma , 2001, British Journal of Cancer.

[33]  Carissa A. Sanchez,et al.  Selectively Advantageous Mutations and Hitchhikers in Neoplasms , 2004, Cancer Research.

[34]  D. Iannitti,et al.  Herceptin and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/neu , 2004 .

[35]  J. Jankowski,et al.  Barrett's metaplasia , 2000, The Lancet.

[36]  C. Buskens,et al.  Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal oesophagus , 2003, Gut.

[37]  J. Gong,et al.  Gene expression in rats with Barrett's esophagus and esophageal adenocarcinoma induced by gastroduodenoesophageal reflux. , 2005, World journal of gastroenterology.

[38]  E. Quigley,et al.  Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma? , 2006, Endoscopy.

[39]  E. Tokunaga,et al.  Activation of PI3K/Akt signaling and hormone resistance in breast cancer , 2006, Breast cancer.

[40]  B. Liu,et al.  Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen. , 1997, Carcinogenesis.

[41]  M. Solaymani-Dodaran,et al.  Mortality Associated with Barrett's Esophagus and Gastroesophageal Reflux Disease Diagnoses—A Population-Based Cohort Study , 2005, The American Journal of Gastroenterology.

[42]  Carissa A. Sanchez,et al.  Genetic clonal diversity predicts progression to esophageal adenocarcinoma , 2006, Nature Genetics.

[43]  M. Omary,et al.  Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. , 2000, Gastroenterology.

[44]  L. Schmidt,et al.  The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants , 2004, Oncogene.

[45]  A. Fendrick,et al.  Screening and Surveillance for Barrett Esophagus in High-Risk Groups: A CostUtility Analysis , 2003, Annals of Internal Medicine.

[46]  G. Hortobagyi,et al.  Targeting HER2: recent developments and future directions for breast cancer patients. , 2001, Seminars in oncology.

[47]  J. Peters,et al.  Gastric juice protects against the development of esophageal adenocarcinoma in the rat. , 1996, Annals of surgery.

[48]  C. Heid,et al.  A novel method for real time quantitative RT-PCR. , 1996, Genome research.

[49]  Carol Coupland,et al.  Risk of oesophageal cancer in Barrett’s oesophagus and gastro-oesophageal reflux , 2003 .

[50]  H. Sugihara,et al.  Cell kinetic study on histogenesis of Barrett's esophagus using rat reflux model. , 2003, Scandinavian journal of gastroenterology.

[51]  Patricia L. Blount,et al.  An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. , 1993, Gastroenterology.

[52]  H. Appelman.  What is dysplasia in the gastrointestinal tract? , 2005, Archives of pathology & laboratory medicine.

[53]  M. Campiglio,et al.  Biologic and therapeutic role of HER2 in cancer , 2003, Oncogene.

[54]  L. Penland,et al.  Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.

[55]  N. Shepherd,et al.  c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus. , 1995, Journal of clinical pathology.

[56]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[57]  Jilin Sun,et al.  Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. , 2006, Cancer research.